

**REMARKS**

Claims 3-34 are pending in the present application. Claims 19 and 32 are amended. Claim 19 is amended to correctly recite "polypeptide of claim 32" rather than "polynucleotide of claim 32," since claim 32 provides antecedent support for a polypeptide. Further, claim 19 is amended to recite a tumor antigen peptide, which is a peptide fragment of the polynucleotide recited in claim 32. Support for a tumor antigen peptide is found in the specification, such as on page 4, lines 21-24. Other amendments are made to merely improve the grammar of the claim. Claim 32 is amended to recite a tumor antigen protein which gives rise to tumor antigen peptide(s) found in the specification, such as on page 6, lines 20-23.

No new matter is inserted into the application by way of these amendments. Entry of the above amendments is earnestly solicited.


Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Kristi L. Rupert, Ph.D. (Reg. No. 45,702) at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

Appl. No. 09/763,985

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
John W. Bailey, #32,881

*KLR*  
JWB/KLR/gml  
0020-4817P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachment: Version with Markings Showing Changes Made

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 19 and 32 are amended as follows:

19. (Twice Amended) An isolated nucleic acid [that encodes] corresponding to a tumor antigen [protein] peptide, [wherein] said tumor antigen [protein gives rise to peptide fragments which are] peptide being a peptide fragment of the protein which is encoded by the [polypeptide] polynucleotide of claim 32, or [are] is produced by the process of claim 5, and [bind] binds to an HLA antigen and [are] being recognized by cytotoxic T lymphocytes.

32. (Amended) An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2,
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1, and
- (c) a polynucleotide which hybridizes with a polynucleotide of any one of (a) to (b), under stringent hybridization conditions comprising 6xSSC, 50% formamide, and 0.5% SDS and a temperature of 42°C,

wherein said polynucleotide encodes a tumor antigen protein[, and peptide fragments thereof bind] which gives rise to tumor antigen peptide(s) that bind(s) to an HLA antigen and are recognized by cytotoxic T lymphocytes.